Latest Articles about ELN

Alkermes Reports Earnings for Q4 - Analyst Blog

Zacks Equity Research — Thu, 23 May 2013 22:07:01 Z

Alkermes plc 's ( ALKS ) fourth quarter of fiscal 2013 (ended Mar 31, 2013) adjusted earnings (including stock-based compensation expense) of 21 cents per share compared favorably to the

Elan Provides Strategic Update - Analyst Blog

Zacks Equity Research — Wed, 22 May 2013 00:27:15 Z

Elan Corporation ( ELN ) recently provided an update on its strategic plans for the future. The company plans several acquisitions and has other strategic initiatives lined up for further

Seth Klarman Buys Warrants, 2 New Stocks

Holly LaFon — Wed, 15 May 2013 23:26:48 Z

Seth Klarman , the legendary investor of the Boston-based Baupost Group, bought four new stocks in the first quarter, according to GuruFocus Real Time Picks Data. He is a cautious value

Elan in Royalty Deal with THRX - Analyst Blog

Zacks Equity Research — Wed, 15 May 2013 01:06:44 Z

Elan Corporation ( ELN ) recently inked a deal with Theravance Inc. ( THRX ) to purchase a participation interest in potential future royalty payments for a one-time cash payment of

Spectrum Pharma Reports 1Q Loss - Analyst Blog

Zacks Equity Research — Tue, 14 May 2013 18:12:01 Z

Spectrum Pharmaceuticals ( SPPI ) reported first quarter of 2013 loss (including stock-based compensation but excluding other special items) of 14 cents per share, narrower than the

Dendreon Narrows 1Q Loss - Analyst Blog

Zacks Equity Research — Fri, 10 May 2013 18:49:01 Z

Dendreon Corporation ( DNDN ) reported first-quarter 2013 loss (including stock-based compensation expenses) of 37 cents per share, narrower than the Zacks Consensus Estimate of a loss of

Positive Data on Forest Combo Drug - Analyst Blog

Zacks Equity Research — Wed, 08 May 2013 00:23:03 Z

Forest Laboratories, Inc. ( FRX ) and Almirall, S.A. recently announced positive top-line data on their chronic obstructive pulmonary disease (COPD) fixed dose combination candidate,

Elan Narrows Y/Y Loss - Analyst Blog

Zacks Equity Research — Thu, 25 Apr 2013 21:09:01 Z

Elan Corporation ( ELN ) reported a loss of 12 cents per share from its continuing operations in the first quarter of 2013, narrower than the year-ago loss of 13 cents per share. Elan's

Elan Turns Down Royalty's Offer - Analyst Blog

Zacks Equity Research — Mon, 22 Apr 2013 21:12:28 Z

Elan Corporation 's ( ELN ) Board of Directors recently rejected Royalty Pharma's offer to acquire all the shares of Elan for $11.25 or less per share. Elan' Board of Directors believed

Elan's Strike Price Stands at $11.25 - Analyst Blog

Zacks Equity Research — Sat, 20 Apr 2013 01:13:49 Z

Elan Corporation ( ELN ) recently announced the final results of its modified Dutch auction tender offer of a maximum aggregate value of $1 billion. The Dutch auction tender offer, which

Elan Responds to Royalty Pharma Offer - Analyst Blog

Zacks Equity Research — Wed, 17 Apr 2013 01:40:01 Z

Elan Corporation 's ( ELN ) Board of Directors recently responded to Echo Pharma Acquisition Limited's ("Royalty Pharma") offer to acquire Elan's shares under Rule 2.5 of the

Elan Gets Takeover Clarity - Analyst Blog

Zacks Equity Research — Fri, 05 Apr 2013 03:08:43 Z

Elan Corporation plc ( ELN ) recently received more visibility regarding its proposed takeover by Royalty Management LLC (Royalty Pharma). The Irish Takeover Panel recently extended the

Elan Sells Off Tysabri Stake - Analyst Blog

Zacks Equity Research — Wed, 03 Apr 2013 22:21:56 Z

Elan Corporation plc ( ELN ) recently closed its Tysabri (natalizumab) collaboration transaction with Biogen Idec ( BIIB ). As a result, Biogen gained full strategic, commercial and

New Data on Biogen/Elan's Tysabri - Analyst Blog

Zacks Equity Research — Wed, 20 Mar 2013 00:44:21 Z

Biogen Idec ( BIIB ) and Elan Corporation plc ( ELN ) recently announced results from several studies of multiple sclerosis drug, Tysabri (natalizumab). Results from the studies showed

Update on Elan's Plans - Analyst Blog

Zacks Equity Research — Tue, 12 Mar 2013 01:08:47 Z

Elan Corporation plc ( ELN ) recently provided an update on its proposed $1billion share repurchase program which is expected to be implemented after the close of the Tysabri (multiple